Acute heart failure: diagnosing and managing acute heart failure in adults
Sinaia 2 Oct 2014 -Final-Acute Heart Failure
-
Upload
bogdanel-mihai -
Category
Documents
-
view
219 -
download
0
Transcript of Sinaia 2 Oct 2014 -Final-Acute Heart Failure
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
1/285
Acute Heart Failure
Prof univ dr Ion C. intoiuȚ
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
2/285
Acute HeartFailure
Prof univ dr Ion C. intoiu
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
3/285
Objectives
• Definitions• Epidemiology• Pathophysiology• Diagnosis
• Management• Summary of Guidelines• Recommended Reading
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
4/285
• Definitions• Epidemiology• Pathophysiology• Diagnosis• Management• Summary of uidelines• !ecommended !eading
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
5/285
"he definition of acute heartfailure has not #een firmly
esta#lished $%&.
It is recogni'ed (hen symptoms ofheart failudevelop rapidly (ithin
hours anddays% in patients (ithout prior
evidence of cardiacdecompensation )
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
6/285
cute !eart "ailure
• !apid onset of symptoms and signsrelated to a#normal cardiac function
• As a result of Systolic Dysfunction*Diastolic Dysfunction* Arrhythmias* orPreload+After load Mismatch
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
7/285
Acute heart failure
AHF,AHF, "he rapid onset of symptoms and signs secondary to a#normalcardiac function.$reduced C-* tissue hypoperfusion congestion* increase in PC/P&
0. /ith or (ithout previous cardiac disease.1. "he cardiac dysfunction can #e related,
a& to systolic or diastolic dysfunction#& to a#normalities in cardiac rhythmc& to preload and afterload mismatch
2. -ften life threatening and re3uires urgent treatment.
"he "as4 Force on Acute Heart Failure of the European Society of"he "as4 Force on Acute Heart Failure of the European Society ofCardiologyCardiology
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
8/285
ESC Guidelines, 2005• DEFI5I"I-5# Rapid onset of symptoms and signs secondary to
abnormal cardiac
function$ %t may occur &ith or &ithout previous cardiac disease$ 'he cardiac dysfunction can be related to
systolic or diastolic dysfunction(abnormalities incardiac rhythm or to pre)load and after load• mismatch *
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
9/285
Acute heart failure is heterogeneousAcute heart failure is heterogeneoussyndromesyndrome
CardiogenicCardiogenicshockshock
PULMONARYPULMONARYEDEMAEDEMA
Right Heart FailureRight Heart Failure
High Output FailureHigh Output FailureH pertensi!e HFH pertensi!e HF
AcuteAcuteDeco"pensatedDeco"pensatedCHFCHF
Filippatos 1667Filippatos 1667
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
10/285
-vervie(, Acute Heart Failure• Comple8 syndrome caused #y
impaired cardiac function• 1 types,
• left ventricular systolicdysfunction $9:SD&
• Heart failure (ith preservede;ection fraction$HFPEF
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
11/285
• Definitions• Epidemiology• Pathophysiology
• Diagnosis• Management• Summary of uidelines• !ecommended !eading
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
12/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
13/285
• Definitions• Epidemiology• Pathophysiology
• Diagnosis• Management• Summary of uidelines• !ecommended !eading
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
14/285
Pathophysiology
-. dysfunction/ccumulation of fluid$
Decrease in 0O !ypoperfusion$
Reciprocal ctivation of 1R S2 3a( &ater retention$
G%% E'4 5 .asopressin$
Refle, activation of S3S/ Epi( 3E$
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
15/285
A Vicious Circle
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
16/285
3atural history of congestive heartfailure
#nitial phase#nitial phase Last ear Last ear
Nor"al heartNor"al heart Chronic heart $ailureChronic heart $ailure% "illion in the U&% "illion in the U&'( "illion in Europe'( "illion in Europe
DeathDeath
#nitial#nitial" ocardial" ocardialin)urin)ur
First ADHF episode*First ADHF episode*Pul"onar ede"aPul"onar ede"aER ad"issionER ad"ission
Later ADHF episodes*Later ADHF episodes*Rescue therapRescue therap#CU ad"ission#CU ad"ission
heorghiade M. Am Cardiol. 1667 $suppl A&,0+> .heorghiade M. Am Cardiol. 1667 $suppl A&,0+> .
H e a r t
+ i a , i l i t
H e a r t
+ i a , i l i t
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
17/285
cute E,acerbations May 0ontribute tothe Progression of the Disease
Gheorghiade M, Fonarow G, Filippatos G et al. Am J Cardiology 2005
Time
V e n
t r i c l a r
! n c
t i o n
Ac te e"ent /ith each event*hemodynamic alterationscontri#ute to progressiveventricular dysfunction.
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
18/285
Clinical CLASIFICATION
Initial and Serial Evaluation ofthe AHF Patient
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
19/285
Acute Heart Failure , Classification
Acute de novo $ ne( onset of AHF in a patient(ithout previously 4no(n cardiacdysfunction 2$or Acute decompensation of chronic heartfailure.
"he "as4 Force on Acute Heart Failure of the European Society of Cardiology"he "as4 Force on Acute Heart Failure of the European Society of Cardiology
Can present itself as,Can present itself as,
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
20/285
illip Classification
Stage I, 3o clinical signs of decompensation$
Stage II /
!eart failure$ Rales( S6( P.!$Stage III,
Severe heart failure$ Pulmonary edema &ith ralesthroughout the lung fields$Stage I:,
0ardiogenic Shoc7/ !ypotension( peripheralvasoconstriction( oliguria( cyanosis and diaphoresis$
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
21/285
"orrester 0lassification
Su#set I13ormal28arm and Dry
Su#set II10ongestion28arm and 8et
Su#set III1!ypoperfusion20old and Dry
Su#set I:10ongestion andhypoperfusion20old and 8et
4
9
6
:
;
Cardiac Inde8$9
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
22/285
Acute Heart Failure , G Clinical severity classification
, #ased on o#servation of the peripheral cir+culation and onauscultation of the lungs for congestion
Class I,
dry and (arm* Class II,
(et and cold* Class III,
cold and dry and Class I:,
cold and (et&.
5ohria A et al, ACC 1662 >0,0B B+0 6>.5ohria A et al, ACC 1662 >0,0B B+0 6>.
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
23/2855ohria A et al, ACC 1662 >0,0B B+0 6>.5ohria A et al, ACC 1662 >0,0B B+0 6>.
drydr y// absence of signs of congestionabsence of signs of congestion (( &et&et// elevated filling pressures(elevated filling pressures(&arm&arm // adeAuate systemic perfusion(adeAuate systemic perfusion( coldcold // inadeAuate systemic perfusioninadeAuate systemic perfusion
GG Clinical severity classificationClinical severi ty classification
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
24/285
Clinical and pathophysiologicalclassification of acute heart failure
More than -(. o$ patients hospitali/ed 0ith heart $ailure ha!e congestion 10et2and sho0 ele!ated PC3P '45
Re$erences* '6 Stevenson LW. Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart ail. !"""#!$%&!'%&(. Availa)le at$ htt $**+++.sciencedirect.com*science* ournal*!- " /%. 56 onaro+ 0C. The treatment tar ets in acute decom ensated
Warm 6 7ry
PC3P7nor"al
C#8 nor"al1co"pensated2
Warm 6 Wet
PC3Pele!ated
C# nor"al
Cold 6 7ry
PC3Plo09nor"al
C# decreased
Cold 6 Wet
PC3Pele!ated
C# decreased
Congestion at rest
Lo0 per$usionat rest
+asodilators4diuretics
No
No
Yes
Yes
Nor"al &+R High &+R
H d i # i G h
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
25/285
Hemodynamic su#sets in Gacute heartfailure #y cardiac inde8
3ormal5ormal
Pulmonaryedema
Cardiacinde89-*'><
reduced #lood pressure
high #lood pressure
Cardiogenicshoc4
Hypovolaemicshoc4
Mor,1.1?Mor,1.1? Mor,06.0?Mor,06.0?
Mor,11.>?Mor,11.>?
Mor,77.7?Mor,77.7?
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
26/285
Acute Heart Failure , Classification
cute decompensated heart failure 1de novo or as decompensation of 0!"2 / 8ith mild signs and
symptoms of !" and do not fulfil criteria for cardio)genic shoc7( pulmonary oedema orhypertensive crisis $
!ypertensive acute heart failure / Signs and symptoms of !" 5 high BP 5 preserved -." 5 chestradiograph findings PO$Pulmonary oedema / .erified by chest C)ray( severe respiratory distress( or)thopnoea &ith SaO 9
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
27/285
Underlying diseases and co!or"idities in acute #eart failure Coronary artery disease
$alvular disease
Prost#etic valve t#ro!"osis
Aortic dissection
AHF and #y%ertension
&enal failure
Pul!onary diseases and "ronc#oconstriction Arr#yt#!ias and AHF
Peri o%erative AHF 'usually due to
!yocardial isc#ae!ia(
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
28/285
0ommon Precipitating "actorsMedication non)adherence$Dietary indiscretion$%nfection 1pneumonia( K'%( etc$2
Renal failure$0ardioto,icHnephroto,icmedication$Kncontrolled hypertension
0ardiac rrhythmiasMyocardial ishemia.alvular disease
Pulmonary embolus0OPD
nemia
'hyroid disorders 3ondihydropyridine 00BSodium retaining medications
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
29/285
Clinical )valuation
Initial and Serial Evaluation ofthe AHF Patient
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
30/285
0linical Presentation.olume Overload -o& 0ardiac Output
DyspneaH"atigueRalesH8heeJing
L.DH!LRH LR PulmonaryHPitting EdemaReduced o,ygen saturation
S6 or S:Electrolyte disturbance%ncreased serum creatinine
3arro& Pulse Pressureltered Mental Status
Pre)renal aJotemia0ool e,tremitiesDecreased urine output
Refractory to %. diuresis
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
31/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
32/285
"he etiology of acute heart failure can varysignificantlly
8 Pri"ar dilatedcardio" opath
8 Acute coronars ndro"
8 Arterial h pertension4dia,etes "ellitus
8 ?o@ic cardio" opath1cocaine4 alchohol2
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
33/285
ADHE!E registry, "reatment ofacute heart failure
• ADHE!E 1Acute Decompensated HE art "ailure 3ational!E gistry2
• Data from 4
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
34/285
Clinical presentation of acute heartfailure in ma;or clinical studies
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
35/285
Clinical presentations of acute heart failurein EHFS II and A9A!M+HF studies
A9A!M+HFEHFS II
Pulmonary oedema $0 ? vs 2B?& and cardiogenic shoc4
$>? vs 01?& are significantly different #et(een the t(o studies.
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
36/285
• Diagnosis Epidemiology• Pathophysiology
• Definition• Management• Summary of uidelines• !ecommended !eading
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
37/285
Diagnosic
• EC• CJ! • AK• 9a#oratory "ests
– A s!all elevationin cardiactro%onin !ay "e
seen in %atients*it# AHF *it#outACS.
• Echo
Di ti h t t
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
38/285
Diagnostic approach to acuteheart failure 160> AHA
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
39/285
Diagnosis-o&)%ntermediate clinical suspicion of D!"
B3P 1 2
B3P ;
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
40/285
Diagnosis, Cardiac Kiomar4ersIn patients (ith symptoms and signs of heartfailure,
Measure serum natriuretic peptides
!efer to have echocardiography and specialistassessment (ithin 1 (ee4s if
+ Previous MI
•K5P L >66 pg66 pg
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
41/285
0ardiac Biomar7ers
"roponin
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
42/285
0linical Potential of B3PH3')
proB3P• E,tensively studied
+ #lood test for heart failure N
• Diagnosis)Raised in -.SDH "H-.!H.!DH 0S• Screening for asymptomatic -.SD• Ris7 stratification Prognosis in established !"
• 'herapy monitoring• 'reatment of !"
3ormal B3P ma7es -.SD very unli7ely
5E A"I:E P!EDIC"I:E :A9NE
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
43/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
44/285
• Definitions• Epidemiology• Pathophysiology• Summary of uidelines• Management
• Summary of uidelines• !ecommended !eading
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
45/285
! H 00 Guideline160> AHA
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
46/285
EVIDENCE
Applying guidelines in acute
heart failure, Facts or fancy O
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
47/285
ACCF6 pages
Canadian Cardiovascular Society
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
48/285
Canadian Cardiovascular SocietyConsensus !ecomendations
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
49/285
Australia
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
50/285
?reat"ent o$ acute heart $ailurealancing R#&B& AND ENEF#?&
$or indi!idual patients
AHF
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
51/285
• Definitions
• Epidemiology• Pathophysiology• Management
$5onpharmacologicaltreatment
.Summary of uidelines• !ecommended !eading
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
52/285
+arious targets $or therapies used in the"anage"ent o$ acute deco"pensated
heart $ailure6
Allen L A 4 and O Connor C M CMA; 5((
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
53/285
5oninvasive ventilation $5I:&
4$ Bilevel positive air&ay pressure1KiPAP& or 9$ 0ontinuous positive air&ay
pressure1CPAP 2$
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
54/285
3oninvasive PP.
Fig. +B
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
55/285
0P P vs$ %ntubation
CPAP• 5on+invasive• Easily discontinued• Easily ad;usted• Nse #y EM"+K• Minimal complications
• Does not re3uiresedation
• Comforta#le
Intu#ation• Invasive• Intu#ated stays intu#ated• !e3uires highly trained
personnel• Significant complications• Can re3uire sedation or
!SI• Potential for infection
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
56/285
Kltrafiltration
• !APID+CHF "rial + >6 patients + ADHF and !enal
Insufficiency $Cr L0.7& + Nltrafiltration had
significant increase influid removal after 1>hours
+ > 76 9 vs 1 2 9
• N59-AD "rial + 166 patients + !enal insufficiency (as
not a criteria for inclusion + Standard care vs ultra
filtration + > Hours >. 9 vs 2.29 + 6 Days fe(er
rehospitali'ations .11 vs .> and fe(er unscheduledclinic visits 10 vs >>
:ption in the setting of failed diureticand vasodilator therapy
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
57/285
Cardiac and :entricular AssistDevices
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
58/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
59/285
9eft :entricular Assist Device
• "he 9:AD assists left ventricular function #y pumping
#lood from left atrium to aorta
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
60/285
!ight :entricular Assist Device
• "he !:AD assists isolated right ventricular dysfunction #y
pumping #lood from right atrium to pulmonary artery
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
61/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
62/285
E0MO
• ECMO removes carbon dioxide from and adds oxygen o venousblood via an ar ificial membranelung
Severe respiratoryfailure Cardiac ailure+ith ina)ility to +ean off;ypass ;ridge toCardiac Transplant
Acute Hert Failure and -perative
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
63/285
Acute Hert Failure and -perativeMortality Prediction Score
• !e3uirement for ventilatorsupport Q > points
• Clinical picture of post+
cardiotomy shoc4 Q 1 points
• Nse of temporary 9:AD prior toHeart+Mate insertion Q 1 points
• Central venous pressure L0mmHg Q 0 point
• Prothrom#in time L0 seconds Q0 point
• Scoring + 6+7, 9o( ris4
• Mortality ?
+ 7+B, Intermediate !is4 • Mortality 21? + +06, High !is4
• Mortality > ?
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
64/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
65/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
66/285
briefdiscussion ofthe &or7s ofthis thing$$$
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
67/285
Ruestions
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
68/285
AFLENAFLEN
Triflusal
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
69/285
THE END
Thank you for your attentionThank you for your attention
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
70/285
NNe0e0 &trategies&trategies
$or $or NTIPL TELETTRETMENT
Prof univ dr Ion C."intoiu
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
71/285
:entricular Assist Device
6
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
72/285
Acute Heart Failure
5on+pharmachologic treatment• Kalance #et(een myocardial o8ygen demand
and delivery• "emperature control• Mechanical circulatory support
• Intraaortic #alloon pump• Cardiopulmonary interaction role of
mechanical ventilation
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
73/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
74/285
Intraaortic Kalloon Pump
.
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
75/285
E8tracorporeral Mem#rane -8ygenation
Advantages disadvantages• Possi#ility of providing total cardiopulmonary support
and allo(ing for cardiac and pulmonary healing* #utneeds for higher level of anticoagulation* leads to#leeding* increased #lood loss* #lood productre3uirement* multiple e8ploration* and potentialinfection
Indications• 5eonatal respiratory failure• Pediatric respiratory failure• 5eonatal and pediatric cardiac failure• Adult cardiorespiratory failure
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
76/285
Mechanical Circulatory Support
"echnical principles• In children* the most common form of :AD involves
use of centrifugal pump• Atrial pressure lines are neccessory to monitor for
ade3uate decompression and 4ept as close to 'ero aspossi#le to ensure ventricular decompression
• All inotropes should #e (ithheld if possi#le during therecovery period
• Serial stress echocardiography should #e performedevery 0+2 days to document progression of recovery
• Decannulation should #e performed #y gradually(eaning :AD support and #e a team approach (ithpreparation of volume catecholamine infusion ready.
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
77/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
78/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
79/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
80/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
81/285
:AD for Pediatric Patients
9imitations of development4 Si'e constraints
9 Differences in pathophysiology of failure 0& !ight ventricular failure
1& Kiventricular failure
2& Pulmonary failure
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
82/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
83/285
9eft :entricular Assist Device
• "he 9:AD assists left ventricular function #y pumping
#lood from left atrium to aorta
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
84/285
!ight :entricular Assist Device
• "he !:AD assists isolated right ventricular dysfunction #y pumping #lood from right atrium to pulmonary artery
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
85/285
Kerlin Heart :AD
• Kerlin Heart :AD is a paracorporeal air+driven pulsatile :AD
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
86/285
arvi4 1666 System
• avi4 1666 is an intraventricular a8ial flo( impeller pump re3uiring
percutaneous electric po(er of possi#le implanted #attery po(er
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
87/285
Kiventricular Assist Device
• "horatec. KI:AD
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
88/285
E8tracorporeral Mem#rane -8ygenation
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
89/285
Cardiopulmonary Support System
Initial and Serial Evaluation of
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
90/285
Clinical )valuation
Initial and Serial Evaluation ofthe AHF Patient
Initial and Serial Evaluation of
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
91/285
,iagnostic Tests
Initial and Serial Evaluation ofthe AHF Patient
Initial and Serial Evaluation of
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
92/285
Noninvasive CardiacI!aging
Initial and Serial Evaluation ofthe AHF Patient
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
93/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
94/285
-ec#anical CirculatorySu%%ort
Guideline for HF
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
95/285
Surgical PercutaneousTranscat#eterInterventional
Treat!ents of AHF
Guideline for HF
Conclusions
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
96/285
• Evidence)based guideline directed diagnosis( evaluation and
therapy should be the mainstay for all patients &ith !"$• Effective implementation of guideline)directed best Auality
care reduces mortality( improves O- and preserves healthcare resources$
• Ongoing research is needed to ans&er the remaining Auestionsincluding/ prevention( nonpharmacological therapy of !"including dietary adjustments( treatment of !" ! E"(management of hospitaliJed !"( effective reduction in !"readmissions( more precise use of device)based therapy(smaller M0S platforms and cell)based regenerative therapy$
Conclusions
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
97/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
98/285
Overvie&/ cute !eart "ailure
• 5e( ESC guidelines• Diagnosis
+ Serum natriuretic peptides• 5on+invasive ventilation• Inotropes• 5esiritide• Cardiac Devices
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
99/285
Objectives
Revie& the pathophysiology of D!"$Describe the clinical presentation of D!"$
pply effective therapeutic strategies using consensusguidelines from the 1!"S 2 and the 1ES02$E,amine the clinical evidence of milrinone and
niseritide in the treatment of D!"$Evaluate the appropriateness of treatment$
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
100/285
D!"
Rapid onset of signs and symptoms secondary to abnormal cardiacfunction due to systolic( diastolic dysfunction( abnormalities incardiac rhythm or to pre)load and after)load mismatch$
De novo or acute decompensation of 0!"$Q;
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
101/285
Acute heart failure
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
102/285
Acute heart failure
AHF,AHF, "he rapid onset of symptoms and signs secondary to a#normalcardiac function.$reduced C-* tissue hypoperfusion congestion* increase in PC/P&
0. /ith or (ithout previous cardiac disease.
1. "he cardiac dysfunction can #e related,a& to systolic or diastolic dysfunction#& to a#normalities in cardiac rhythmc& to preload and afterload mismatch
2. -ften life threatening and re3uires urgent treatment.
"he "as4 Force on Acute Heart Failure of the European Society of"he "as4 Force on Acute Heart Failure of the European Society ofCardiologyCardiology
Hemodynamic su#sets in Gacute heartfailure
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
103/285
failure
3ormal5ormal
Pulmonary
edema
C
ardiacinde89-*'><
reduced #lood pressure
high #lood pressure
Cardiogenic
shoc4
Hypovolaemicshoc4
Mor,1.1?Mor,1.1? Mor,06.0?Mor,06.0?
Mor,11.>?Mor,11.>?
Mor,77.7?Mor,77.7?
Acute Heart Failure ,
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
104/285
-ther Classifications%n !" after M%( best applied to acute denovo heart failure/%n !" after M%( best applied to acute denovo heart failure/
'he illip classification / based on clinical signs and chest C)ray findings 1Stage %/ 3o heart failure( Stage %%/ !eartfailure( Stage %%%/ Severe heart failure and Stage %./ 0ardiogenic shoc72$'he "orrester classification/ based on clinical signs and haemodynamic cha)racteristics$
%n a cardiomyopathy service( best applied to chronic decompensated heart failure/%n a cardiomyopathy service( best applied to chronic decompensated heart failure/ 0linical severity classificationN /
based on observation of the peripheral cir)culation and on auscultation of the lungs for
congestion10lass %/ dry and &arm( 0lass %%/ &et and cold( 0lass %%%/ cold and dry and 0lass %./ cold and&et2$
3ohria et al/ L 00 9)4=
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
105/285
cute decompensated heart failure 1de novo or as decompensation of 0!"2 / 8ithmild signs and symptoms of !" and do not fulfil criteria for cardio)genic shoc7(
pulmonary oedema or hypertensive crisis $!ypertensive acute heart failure / Signs and symptoms of !" 5 high BP 5 preserved-." 5 chest radiograph findings PO$Pulmonary oedema / .erified by chest C)ray( severe respiratory distress( or)thopnoea
&ith SaO 9
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
106/285
H! SKP CI P08P 0ongestionillipH
"orrester
Diuresis !ypo) perfusion
End organhypo)
perfusion
%. Acutedecompensatedcongestive heartfailureU
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
107/285
!or idities in acute #eart failure Coronary artery disease
$alvular disease
Prost#etic valve t#ro!"osis
Aortic dissection
AHF and #y%ertension
&enal failure
Pul!onary diseases and "ronc#oconstriction
Arr#yt#!ias and AHF
Peri o%erative AHF 'usually due to!yocardial isc#ae!ia(
4oals of treat!ent of t#e %atient*it# ac te #eart fail re
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
108/285
Clinical↓ sy!%to!s 'dys%nea and or fatigue( clinical signs
"ody *eig#t diuresis
o/ygenationLa"oratory e/a!inations +UN and or creatinine seru! electrolyte nor!alisation↓ %las!a +NP
"lood glucose nor!alisationHae!odyna!ic%ul!onary *edge %ressure to 0 12 !! Hg
cardiac out%ut and or stro3e volu!e
*it# acute #eart failure
"he "as4 Force on Acute Heart Failure of the European Society of Cardiology"he "as4 Force on Acute Heart Failure of the European Society of Cardiology
4oals of treat!ent of t#e %atient
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
109/285
*it# acute #eart failure
Outco!e length of stay in the intensive care unit duration of hospitali'ation
time to hospital re+admission mortality Tolera"ility9o( (ithdra(al rate
9o( incidence of adverse effects
"he "as4 Force on Acute Heart Failure of the European Society of Cardiology"he "as4 Force on Acute Heart Failure of the European Society of Cardiology
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
110/285
cute E,acerbations May 0ontribute tothe Progression of the Disease
Gheorghiade M, Fonarow G, Filippatos G et al. Am J Cardiology 2005
Time
V e n
t r i c l a r ! n c t
i o n
Ac te e"ent /ith each event*hemodynamic alterationscontri#ute to progressiveventricular dysfunction.
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
111/285
illip 0lassification
Stage %/ 3o clinical signs of decompensation$Stage %%/ !eart failure$ Rales( S6( P.!$
Stage %%%/ Severe heart failure$ Pulmonary edema &ithrales throughout the lung fields$Stage %./ 0ardiogenic Shoc7/ !ypotension( peripheralvasoconstriction( oliguria( cyanosis and diaphoresis$
"orrester 0lassification
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
112/285
orrester 0lassification
Su#set I13ormal2
8arm and Dry
Su#set II10ongestion2
8arm and 8et
Su#set III
1!ypoperfusion20old and Dry
Su#set I:
10ongestion andhypoperfusion20old and 8et
4
9
6
:
;
Cardiac Inde8$9
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
113/285
0ommon Precipitating "actorsMedication non)adherence$Dietary indiscretion$%nfection 1pneumonia( K'%( etc$2Renal failure$0ardioto,icHnephroto,icmedication$Kncontrolled hypertension0ardiac rrhythmiasMyocardial ishemia.alvular disease
Pulmonary embolus0OPD
nemia'hyroid disorders
3ondihydropyridine 00BSodium retaining medications
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
114/285
0linical Presentation.olume Overload -o& 0ardiac Output
DyspneaH"atigueRalesH8heeJing
L.DH!LRH LR PulmonaryHPitting EdemaReduced o,ygen saturationS6 or S:Electrolyte disturbance%ncreased serum creatinine
3arro& Pulse Pressureltered Mental Status
Pre)renal aJotemia0ool e,tremitiesDecreased urine outputRefractory to %. diuresis
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
115/285
Differential Diagnosis
PneumoniaReactive air&ay disease
Pulmonary embolus
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
116/285
Diagnosis
Diagnosis of D!" should be primarily based on signs and symptoms$ 102
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
117/285
Diagnosis-o&)%ntermediate clinical suspicion of D!"
B3P 1 2
B3P ;
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
118/285
Predictors of Mortality
BK3 :6 mgHdl
SBP 44; mm!gs0r 9$>; mgHdl
"onaro& G0 et al$ JAMA" 9
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
119/285
Diagnosis, Cardiac Kiomar4ersIn patients (ith symptoms and signs of heartfailure,
Measure serum natriuretic peptides
!efer to have echocardiography and specialist
assessment (ithin 1 (ee4s if
+ Previous MI
•K5P L >66 pg66 pg
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
120/285
0ardiac Biomar7ers
"roponin
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
121/285
) yp9U
Acute M#
? pe ' ? pe 5 ? pe > ? pe
? pe a
? pe %
? pe ,
Secondary tospasm,
embolism, anaemia,arrhythmia, BP
changes
Tro%oninitis
0linical Potential of B3PH3')
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
122/285
0linical Potential of B3PH3 ) proB3P
• E,tensively studied + #lood test for heart failure N
• Diagnosis)Raised in -.SDH "H-.!H.!DH 0S• Screening for asymptomatic -.SD• Ris7 stratification Prognosis in established !"• 'herapy monitoring• 'reatment of !"
3ormal B3P ma7es -.SD very unli7ely5E A"I:E P!EDIC"I:E :A9NE
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
123/285
Overvie&/ cute !eart "ailure
• 3e& ES0 guidelines• Diagnosis
+ serum natriuretic peptides• 5on+invasive ventilation• %notropes
• 3esiritide• 0ardiac Devices
cute 0ardiogenic Pulmonary Oedema
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
124/285
• 0ommon + 4;)9
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
125/285
%nitial 'reatment
• The evidence infavour of morphineuse for AHF islimited
• Multiple agents are usedto manage !"( butthere is a pa city o!clinical trials data andtheir se is largelyempiric $
• Most agents improvehaemodynamics but noagent has #een shownto red ce mortality $
3on)invasive .entilation %n cute 0ardiogenicPulmonary Oedema
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
126/285
Pulmonary Oedema
!"hen the household vacuum cleaner is employed,the machine should be run for some minutes #rst of
all to get rid of dust$
Poulton %P, &'on ()* +eft sided heart failure -ithpulmonary oedema* .ts treatment -ith the /pulmonary
plus pressure machine / Lancet 0123456731*281 283
Physiological %mprovement &ith 0P P in Patients&ith 0PO
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
127/285
9ell et al Eur Heart 7::7
&ith 0PO
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
128/285
Mortality reducedfrom 99F to 44F
RR
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
129/285
Kac4groundims
• 0linical effectiveness of non)invasive ventilation
• 0omparative effectiveness of0P P and 3%PP.• Safety of non)invasive ventilation
!ypothesis/
• 3on)invasive ventilation reducesmortality
Intervention• Randomised 14/4/42
+ Standard o,ygentherapy 1by facial mas72 + 0P P 1; cm! 9O up
titrated to a ma,imumof 4; cm! 9O2 + 3%PP. 1=H: cm! 9O up
titrated to a ma,imumof 9
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
130/285
Mor ali y
Standard"herapy
5on+Invasive
:entilation
-dds !atio 7?Confidence
Intervals
P :alue
B+Day . ? .7? 6. B 6. 2 to 0.> 6.
26+Day 0 .B? 07.>? 6. 2 6. 7 to 0.21 6. 7
Active Trial 1:42 patients @ 3=: per armBaseline ?haracteristics matchedBaseline )edications matched
Outcome/ !ospital stay3?P&
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
131/285
Standard CPAP 5IPP: P+value
Admitted to intensiveCare
. ? .0? . ? 6.>00
Admitted to high+dependency Care
B.B? 06.2? 06. ? 6.260
Admitted to coronaryCare
2 .0? >2.B? >6. ? 6.22B
Median length of hospitalstay in days $ IR!&
$7+02& $7+0 & $7+0 & 6.202
o si ni#cant di erences PC: :=
0O30 KS%O3S3?P&
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
132/285
0O30-KS%O3S
• In patients (ith acute cardiogenic pulmonaryoedema non+invasive ventilation $06 patients&
Produces more rapid resolution of meta#olic a#normalitiesand respiratory distress
Has no ma;or effect on B+day or 26+day mortality
Is #eneficial irrespective of the mode $CPAP or 5IPP:& ofdelivery
O i &/ ! " il
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
133/285
Overvie&/ cute !eart "ailure
• 3e& ES0 guidelines• Diagnosis
+ serum natriuretic peptides• 3on)invasive ventilation• %notropes
• 3esiritide• 0ardiac Devices
' l d BP
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
134/285
'reatment related to BP
!espiratory support* Furosemide $infusion&I: Do#utamine plus lo( dose I: "5
V IAKP
Oth t t t ti
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
135/285
Other treatment options
• .asopressin antagonists + Knproven
• -evosimendan is a calciumsensitiser that improvescardiac contractility
• E,erts significantvasodilatation mediatedthrough 'P)sensitive
potassium channels
• -evosimendan infusionincreases cardiac outputand stro7e volume andreduces pulmonary &edge
pressure( systemic vascularresistance( and pulmonaryvascular resistance$
• .asopressors
1norepinephrine2 are notrecommended as first)lineagents
O i &/ t ! t " il
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
136/285
Overvie&/ cute !eart "ailure
• 3e& ES0 guidelines• Diagnosis
+ serum natriuretic peptides• 3on)invasive ventilation• %notropes
• 3esiritide• 0ardiac Devices
0auses of death in heart failure
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
137/285
0auses of death in heart failure
Pump failurePump failure
Other Other
Sudden deathSudden death
49F49F
9:F9:F@:F@:F
3V! %% 3V! %%
9@F9@F
4;F4;F; F; F
3V! %%% 3V! %%%
;@F;@F
44F44F
66F66F
3V! %. 3V! %.
. o +imitation
.. S&B on severee'ertion... S&B on mild
e'ertion
Pre)implant counselling!o& do you &ant to dieU
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
138/285
!o& do you &ant to dieUHeart failure death Sudden death
Device C Rays
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
139/285
y
ICD 9ead Ki: 9: 9ead position
%0D Myths
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
140/285
%0D Myths
• Myths + %0Ds prevent syncope + 0ontacts can be electrocuted by
%0D discharge
+ 3ot safe to use mobile phone(mirco&ave( playstation etc$ + 8ill stop you dying from ."
• Diathermy 7ills patients devicesN
+ PPM + may inhibit 1pulseo,imetry2
+ %0D + &ill detect as ."1reprogram2
0onseAuences of tachycardia therapy
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
141/285
:" Storm Inappropriate shoc4s
End of life issues/ 3E0 3
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
142/285
End of life issues/ 3E0.3
.entricular arrhythmias andHor poor -. function W is an %0D indicated U'emporarily disabled &ith a ring magnet
'he "utureU
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
143/285
he utureU
.ntrathoracic .mpedance* ?oncept
'he Reality
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
144/285
(rierlungsmeanstheintrathor
"etterlungsmeanstheintrathor
+essFluid
)oreFluid
he Reality
Epidemiology
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
145/285
Mortality is appro,$ ;
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
146/285
Objectives
Revie& the pathophysiology of D!"$Describe the clinical presentation of D!"$
pply effective therapeutic strategies using consensusguidelines from the 1!"S 2 and the 1ES02$E,amine the clinical evidence of milrinone andniseritide in the treatment of D!"$Evaluate the appropriateness of treatment$
D!"
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
147/285
D!
Rapid onset of signs and symptoms secondary to abnormal cardiacfunction due to systolic( diastolic dysfunction( abnormalities incardiac rhythm or to pre)load and after)load mismatch$ De novo or acute decompensation of 0!"$Q;
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
148/285
-. dysfunction/ccumulation of fluid$
Decrease in 0O !ypoperfusion$
Reciprocal ctivation of 1R S2 3a( &ater retention$
G%% E'4 5 .asopressin$
Refle, activation of S3S/ Epi( 3E$
illip 0lassification
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
149/285
illip 0lassification
Stage %/ 3o clinical signs of decompensation$Stage %%/ !eart failure$ Rales( S6( P.!$Stage %%%/ Severe heart failure$ Pulmonary edema &ithrales throughout the lung fields$Stage %./ 0ardiogenic Shoc7/ !ypotension( peripheralvasoconstriction( oliguria( cyanosis and diaphoresis$
"orrester 0lassification
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
150/285
Subset %13ormal2
8arm and Dry
Subset %%10ongestion2
8arm and 8et
Subset %%%
1!ypoperfusion20old and Dry
Subset %.
10ongestion andhypoperfusion20old and 8et
4
9
6
:
;
0ardiac %nde,
1-HminHm92
9$9-HminHm9
3ohria et al$ JAMA$9
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
151/285
0linical Presentation
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
152/285
0linical Presentation.olume Overload -o& 0ardiac Output
DyspneaH"atigueRalesH8heeJing
L.DH!LRH LR PulmonaryHPitting EdemaReduced o,ygen saturationS6 or S:Electrolyte disturbance%ncreased serum creatinine
3arro& Pulse Pressureltered Mental Status
Pre)renal aJotemia0ool e,tremitiesDecreased urine outputRefractory to %. diuresis
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
153/285
Diagnosis
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
154/285
Diagnosis
Diagnosis of D!" should be primarily based on signs and symptoms$ 102
Diagnosis
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
155/285
Diagnosis-o&)%ntermediate clinical suspicion of D!"
B3P 1 2
B3P ;
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
156/285
Predictors of Mortality
BK3 :6 mgHdl
SBP 44; mm!gs0r 9$>; mgHdl
"onaro& G0 et al$ JAMA" 9
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
157/285
Goals of herapy
%mprove symptoms and signs of congestion andHorhypoperfusion$Reverse hemodynamic abnormalities$
%dentify the etiology$MinimiJe side effects$OptimiJe therapy$ -ength of stay( mortality( time to hospital
readmission$Educate patients on medications and self assessmentof !"$
'reatment Strategy
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
158/285
Establish a DiagnosisO,ygen and .entilatory ssistanceSymptom Relief
nticoagulation!emodynamic Support/
DiuresisH"luids
.asodilators%notropes
.asopressors
ssess Patient Responsenti)infectives
Glucose 0ontrol
'he Principle
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
159/285
he Principle
Diuretics
%notropes
.asodilators
Reduce "luid OverloadReduced Preload/ 1E)D.f2( P08P
%ncrease 0ontractility%ncrease 0O( E"( Perfusion
Reduce PreloadReduce fterload
ssess SignsHSymptomsHDetermine!emodynamic Status
E0 %nterventions/
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
160/285
E0 %nterventions/0ardiac panel/ 10B0 &Hdiff platelets( SM )>
0 )MB( Glucose2( 'S!(Po,( E0G( B3P( C)ray
0onsideralternative diagnosis
Does Patient presents &ithDistress or pain U
0P P
3%PP
3ormal
O,ygen 0
bnormal
Evaluate cardiac function by 9DE
0haracteriJe type and severity
Metoprolol ; mg % %%b0
%s patient hypo,icUVes
3o but difficult breathing
Morphine 6 mg %.PB %%bByes
Does patient present &ith ischemic chest pain resistant to opiates or tachycardiaU
.olume Overloaded$A&M d l O l d
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
161/285
%. Diuretics"urosmide 9
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
162/285
I: Diuretics
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
163/285
SBP =;)4;ugH7g%.PB over4
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
164/285
'ransient use of .asopressor therapy
Epinephrine
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
165/285
O,ygen Saturation0B0BPE0GB3PSigns/
Edema( Rales( scites( !epatomegaly( L.DSymptoms/
Orthopnea( P3D( Dyspnea( "atigue( 0ough 3egativeHpositive balance
ElectrolytesKrinalysisBK3HScr
BG
1OP'%ME)0!"2
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
166/285
1OP %ME)0! 2Outcomes of a Prospective 'rial of%ntravenous Milrinone for E,acerbations of
0hronic !eart "ailure
JAMA, March 9> 9
Objective/ 'o prospectively test &hether a strategy that includes short+term
use of milrinone in addition to standard therapy can improve clinical outcomesof patients hospitaliJed &ith an e,acerbation of chronic heart failure$
Study Design
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
167/285
Study DesignProspective randomiJed double)blind placebo)controlled trial$%'' $
Similar baseline characteristics$RandomiJation to a := hour infusion of eithermilrinone 1n Z :>>2 or placebo 1 :>92$Milrinone treatment arm/ Started &ith an initialinfusion of
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
168/285
Primary Efficacy Outcome/'he total number of days hospitaliJed for cardiovascular causes ordays decreased &ithin the @< days after randomiJation$
Secondary endpoints/"ailed therapy because of adverse events$"ailed therapy because of &orsening heart failure$ Proportion of patients achieving target doses of 0E)% therapy$
'ime to achieve target 0E)% dose$Symptom improvement in !" score$
Patient Selection
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
169/285
at e t Se ect o%nclusion 0riteria E,clusion 0riteria
4= yoaDemonstrated -.E" :
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
170/285
'reatment &ith milrinone did not reduce the primaryendpoint of days hospitaliJed for cardiovascular causes&ithin @< days compared &ith placebo$
Results 1contI2
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
171/285
'reatment failure cause at := hours/dverse event
Events during hospitaliJation/M%
3e& atrial fibrillationHflutter .entricular tachycardiaHfibrillationSustained hypotension
Placebo1nZ:>92
Milrinone1n Z :>>2 P value
9$4F 49$@F
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
172/285
Study did not directly address patients &ithacutely decompensated chronic heart failure for&hom inotropic therapy is essential$
3on)formal therapeutic protocol$0onfounding variables$
0onclusions
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
173/285
Results do not support the routine use ofmilrinone in patients hospitaliJed &ith ane,acerbation of chronic heart failure$
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
174/285
Study Design
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
175/285
y g
RandomiJed double)blind( double dummy trial$Patients &ere stratified to catheteriJed 1nZ9:@2 andnon)catheteriJed 1nZ 9:62Patients &ere then randomiJed to fi,ed dose nesiritide(adjustable dose niseritide( nitroglycerin or placbo forthe first 6 hours$
fter 6 hours patients &ere in the double dummydesign of nesiritide and nitroglycerin treatment arms$
Outcome Measures
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
176/285
Primary Endpoint/ 0hange in P08P and patientIsself)evaluation of dyspnea from baseline at 6hours$
Secondary Endpoints/Onset of effect on P08PEffect on P08P 9: hrs after the start of study drugSelf)assessed dyspnea and global clinical statusOverall safety profile$
%nclusion
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
177/285
%nclusion 0riteria E,clusion 0riteria
Dyspnea at rest0ardiac etiology of dyspnea
SBP <.olume depletion0% to %. vasodilatorsMechanical ventillationSurvival less than 6; days
Results
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
178/285
Reduction in P08P &as greater in thenesiritide group &ith the first measurement$Beyond 9:hr the difference in P08P bet&een
nesiritide and nitroglycerin &as insignificant$%mprovement in dyspnea and global clinicalstatus scores in the nesiritide and nitroglycerin
&ere not significantly different at any time$! &as more common in the 3itroglyceringroup$
-imitations
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
179/285
!eterogenous patient population'herapeutic protocol$
ssessment of mortalityHmorbidity
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
180/285
CC, 8ea7ness and Shortness of Breath $
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
181/285
>
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
182/285
Medications at Home, tenolol 9; mg Ad( pantopraJole :; mg Ad(
acetaminophen ;
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
183/285
PhysicianWs assessment
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
184/285
0. Congestive Heart Failure, Patient &ill receive %.diuretics and monitor for electrolytes$
1. N"I, 0ontinue 0ipro until the completion of the course$
2. A#normal cardiac en'ymes, Represent myocardialinjury$ 0ardiology consulted$>. Acute !enal insufficiency, Monitor creatinine( diuresis
and BP$
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
185/285
! H 00 Guideline160> AHA
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
186/285
Nishi"ura R A et al6 Circulation6 5(' ='5-*e%5' e >
Copyright 9 American Heart Association< =nc. All rights reserved.
Diagnosis and ?reat"ent o$ #E6 7Earl surger de$ined as during initial hospitali/ation ,e$oreco"pletion o$ a $ull therapeutic course o$ anti,iotics6
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
187/285
Nishi"ura R A et al6 Circulation6 5(' ='5-*e%5' e >
Copyright 9 American Heart Association< =nc. All rights reserved.
"he definition of acute heartfailure has not #een firmly
esta#lished $%&.
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
188/285
It is recogni'ed (hen symptoms ofheart failudevelop rapidly (ithin
hours anddays% in patients (ithout prior
evidence of cardiacdecompensation )
Drug NsualDose
⍺ [4 [9 .asodilati
on
.asoconstri,n
%notro pic
0hronotropic
H! MAP PAP P/P C:P S:! S: C-
Epinephrine1 drenaline2
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
189/285
\gH7gHmin14):
\gHmin2
555 55 55 ) 555 55 55
3orepinephrine1-evophed2
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
190/285
ne1Dobutre
,2
\gH7gHmin ] ]
Milrinone1Primacor
2
-D ;< \gH7gover 4< min$(then ;)
;\gH7gHmin
) ) ) 555
) 555 5 OH]
^ ^ ^ OH^
^ ] ]
Gilman G( Rall '8$( et al$ Goodman and GilmanIs 'he Pharmacological Basis of 'herapeutics$ = th ed$ 4 6$Marino P$ 'he %0K Boo7$ 9 nd ed$ 4 =$ Voung -$( oda) imble M$ pplied 'herapeutics$ @ th ed$ 4 ;$ irby R$( 'aylor R$( et$ al$ !andboo7 of 0ritical 0are$ 9 nd ed$ 4 >$Darovic G$( "ran7lin 0$ !andboo7 of !emodynamic Monitoring$ 4 $
5uove prospettive nel trattamentodello scompenso acuto
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
191/285
Michele Emdin*Fonda'ione a#riele Monasterio* Pisa
Congresso regionale A$MC% Toscana,Viareggio, & %TT%'() 20**
Acute Heart Failure Syndrome$s&
• A t h t f il $AHF& i d fi d id t
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
192/285
• Acute heart failure $AHF& is defined as a rapid onset
or change in the signs and symptoms of HF* resultingin the need for urgent therapy.
• Symptoms are primarily the result of severepulmonary congestion due to elevated left ventricular$9:& filling pressures $(ith or (ithout lo( cardiac
output&.
• AHFS can occur in patients (ith preserved or reducede;ection fraction $EF&.
• Conc rrent cardio"asc lar conditions s ch as coronaryheart disease +C - , hypertension, "al" lar heartdisease, atrial arrhythmias, and/or noncardiacconditions +incl ding renal dys! nction, dia#etes, anemia are o!ten present and may precipitate orcontri# te to the pathophysiology o! this syndrome
AHFS, 5-" :E!IFIED %
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
193/285
EKM in AHFSO• "he first randomi'ed place#o+controlled AHFS trials
(ere pu#lished as late as 1661
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
194/285
(ere pu#lished as late as 1661.Cuffe MS* et al. f or the -utcomes of a Prospective "rial of Intravenous Milrinone for E8acer#ations of Chronic Heart Failure $-P"IME+CHF&
Investigators. Effects of short+term* intravenous milrinone on acute e8acer#ation of chronic heart failure, a randomi'ed controlled trial. JAMA. 1661
1 B, 07>0=07>B.
Pu#lication Committee for the :MAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure, a
randomi'ed controlled trial. JAMA. 1661 1 B, 0720=07>6
• 5one of the place#o+controlled AHFS studies conductedto date has sho(n either a consistent improvement of in+hospital or postdischarge survival or a decrease inreadmissions.
AHFS = oals of treatment• X Emergency treatment phase
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
195/285
g y p• Improve symptoms• !estore o8ygenation• Improve organ perfusion and haemodynamics• 9imit cardiac
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
196/285
of therapy O• "raditionally* reduction in pulmonary capillary
(edge pressure $PC/P& and
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
197/285
• "he emergency
treatment phase
Patient Selection and 'reatmentCongestion at !est
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
198/285
YesNo
3ar" J Dr>CW> normal
C= normal 4compensated5
Cold J 3et>CW> elevatedC= decreased
Cold J Dr>CW> lo+*normal
C= decreased
Vasodilators?itroprusside?itroglycerin
#notropic DrugsDo,uta"ine
MilrinoneCalciu" &ensiti/ers
?ormal SV1
HighSV1
9o(Perfusion
at !est
No
Yes
3ar" J 3et>CW> elevated
C= normal
?atriuretic>eptide?esiritide or
Stevenson LW. Eur J Heart Fail. 1999;1:251 .
&eco!!ended a%%roac# to t#e use of inotro%ic su%%ort in%atients #os%itali=ed *it# acute HF e/acer"ation
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
199/285
?opyright E7:1: American Heart Association
4old#a"er5 6. I. et al. Circulation 78189171:1;
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
200/285
Intravenous loop diuretics may improve symptoms and fluid loss initially #ut also
may contri#ute to renal function decline. "his may #e related not only tointravascular volume depletion #ut also to further neurohormonal activationresulting in a vasomotor nephropathy.
• Intravenous loop diuretics may #e associated (ith (orse outcomes in AHFS patients.
• 3notropic Therapy
Intravenous inotropes increase myocardial o8ygen consumption* causing myocardialdamage in the setting of hi#ernating myocardium. Nse of inotropes has consistently#een associated (ith increased mortality.
• VasodilatorsE8cessive vasodilatation in AHFS may lead to #lood pressure decrease* potentiallye8acer#ating myocardial ischemia and renal hypoperfusion.
AHFS, (hich appropriate targetsof therapy O
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
201/285
Perspectives• Managing fluids*
• Preserving renal function
AHFS, (hich appropriate targetsof therapy O
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
202/285
o t e apy O
• Contractility
• Diastole
AHFS, 5on farmachologicaltherapy
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
203/285
py
• :asomotion
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
204/285
AHFS (here are (eO /here are (e goingO
• AHFS is a comple8 condition (ith su#stantial mor#idity and mortality andenormous utili'ation of health resources and cost.
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
205/285
• "here are numerous challenges in caring for this population.• Nniform AHFS classification is currently lac4ing* and management
strategies vary mar4edly.
• "here is a general consensus that to reduce mortality* mor#idity* and theeconomic #urden of AHFS* systematic research efforts on clinical applicationand translation of promising #asic science results are needed.
• Pathophysiologically #ased interventions $eg* cardiorenal syndrome& may #eparticularly appealing.
• A special focus should #e on choice of appropriate management strategies*including minimi'ing the use of drugs (ith adverse effects and developmentand validation of 4no(n prognostic mar4ers to guide AHFS interventions .
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
206/285
C-5C9NSI-5...of note* every large pu#lished clinical trialconducted in patients (ith AHFs has #een negativein terms of efficacy* safety* or #oth.
%Ho(ever* most international multicenter clinical
trials completed to date (ere conducted on fairlyundifferentiated populations of patients (ith AHFs.
%.homogeneous pathophysiological disease states(ithin the heterogeneity of aHFs is of paramount
importance to clinical trial design and aHFs therapy.
% Future trials conducted in aHFs must a#andonthe Yone+si'efits+ allW approach in favor of anapproach that ta4es into account the varied anddistinct pathophysiologies of aHFs.
o@ 56
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
207/285
Allen L A 4 and O Connor C M CMA; 5((
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
208/285
Fig6 '* Appro@i"ation o$ cardiac s stolic $unction and cardiac $illing pressures in !ariousacute illnesses6>(6
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
209/285
Allen L A 4 and O Connor C M CMA; 5((
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
210/285
Allen L A 4 and O Connor C M CMA; 5((
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
211/285
Allen L A 4 and O Connor C M CMA; 5((
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
212/285
AHF,AHF, "he rapid onset of symptoms and signs secondary to a#normalcardiac function.$reduced C-* tissue hypoperfusion congestion* increase in PC/P&
0. /ith or (ithout previous cardiac disease.1. "he cardiac dysfunction can #e related,
a& to systolic or diastolic dysfunction#& to a#normalities in cardiac rhythmc& to preload and afterload mismatch
2. -ften life threatening and re3uires urgent treatment.
"he "as4 Force on Acute Heart Failure of the European Society of"he "as4 Force on Acute Heart Failure of the European Society ofCardiologyCardiology
Acute Heart Failure ,-ther Classifications
%n !" after M%( best applied to acute denovo heart failure/%n !" after M%( best applied to acute denovo heart failure/
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
213/285
'he illip classification / based on clinical signs and chest C)ray findings 1Stage %/ 3o heart failure( Stage %%/ !eartfailure( Stage %%%/ Severe heart failure and Stage %./ 0ardiogenic shoc72$'he "orrester classification/ based on clinical signs and haemodynamic cha)racteristics$
%n a cardiomyopathy service( best applied to chronic decompensated heart failure/%n a cardiomyopathy service( best applied to chronic decompensated heart failure/ 0linical severity classificationN /
based on observation of the peripheral cir)culation and on auscultation of the lungs forcongestion
10lass %/ dry and &arm( 0lass %%/ &et and cold( 0lass %%%/ cold and dry and 0lass %./ cold and&et2$
3ohria et al/ L 00 9)4=
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
214/285
mild signs and symptoms of !" and do not fulfil criteria for cardio)genic shoc7( pulmonary oedema or hypertensive crisis $!ypertensive acute heart failure / Signs and symptoms of !" 5 high BP 5 preserved-." 5 chest radiograph findings PO$Pulmonary oedema / .erified by chest C)ray( severe respiratory distress( or)thopnoea&ith SaO 9
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
215/285
decompensated
congestive heartfailure
H!igh
!igh
%% cute heartfailure &ithhypertensionHhypertensive crisis
Ksuallyincreased
!igh 5H) 4= %%) %.H "%%)%%%
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
216/285
$alvular disease Prost#etic valve t#ro!"osis
Aortic dissection
AHF and #y%ertension
&enal failure
Pul!onary diseases and "ronc#oconstriction
Arr#yt#!ias and AHF
Peri o%erative AHF 'usually due to!yocardial isc#ae!ia(
Clinical
4oals of treat!ent of t#e %atient*it# acute #eart failure
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
217/285
Clinical↓ sy!%to!s 'dys%nea and or fatigue( clinical signs
"ody *eig#t diuresis o/ygenation
La"oratory e/a!inations +UN and or creatinine seru! electrolyte nor!alisation↓ %las!a +NP "lood glucose nor!alisationHae!odyna!ic
%ul!onary *edge %ressure to 0 12 !! Hg cardiac out%ut and or stro3e volu!e
"he "as4 Force on Acute Heart Failure of the European Society of Cardiology"he "as4 Force on Acute Heart Failure of the European Society of Cardiology
Patient (ith AHF, immediate treatment goals
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
218/285
"he "as4 Force on Acute Heart Failure of the European Society of Cardiology"he "as4 Force on Acute Heart Failure of the European Society of Cardiology
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
219/285
O/ygen in acute #eart failure Target Sa& 7 02= – 28 5 Class I5 LO) C
&7 administration in hypo'aemic patients -ith acute heart
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
220/285
7 yp p
failure
Class IIa5 LO) C
o &7
0or ↑ Fi&75 in patients -ithout evidence of
hypo'aemia
Hypero'ia causes harm*
coronary "lood >o*5
cardiac out%ut
"lood %ressure"he "as4 Force on Acute Heart Failure of the European Society of Cardiology"he "as4 Force on Acute Heart Failure of the European Society of Cardiology
Non ? invasive ventilation 'NI$(and intu"ation 'TI( in acute #eart
failureGse of CPAP and NIPP$ in acute cardiogenic
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
221/285
pulmonary oedema is associated -ith a signi#cantreduction in the need for endotracheal intubation 0T.5
and mechanical ventilation )D, 'Class IIa5 LO) A( I
T.I. '-$( use* To reverse induced respiratory muscle
fa tigue 0lo- respiratory rate, hypercapnia, confusion5*
a5 .ntervention
b5 &nly if acute respiratory failure does notrespond to vasodilators, & 7 andJor ?PAP or
.PPD"he "as4 Force on Acute Heart Failure of the European Society of Cardiology"he "as4 Force on Acute Heart Failure of the European Society of Cardiology
4uidelines for %ul!onary artery cat#eter'PAC( use in acute #eart failure
• Insertion of PAC for the diagnosis of acute heart failure
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
222/285
is usually unnecessary
• PAC can #e used to distinguish #et(een a cardiogenic
and a not cardiogenic mechanism in comple8 patients
(ith concurrent cardiac and pulmonary disease.• PAC is fre3uently used to estimate hemodynamic
varia#les and guide therapy in the presence of severe
diffuse pulmo+nary pathology or ongoing
haemodynamic compromise not resolved #y initial
therapy
"he "as4 Force on Acute Heart Failure of the European Society of Cardiology"he "as4 Force on Acute Heart Failure of the European Society of Cardiology
$Class II#* 9-E+C&
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
223/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
224/285
3on)pharmacologic Management
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
225/285
Surgical treat!ent inacute #eart failure
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
226/285
0hronic !")End Stage D!" Collabora ive Managemen
• 5onpharmacologic therapies 1contId2
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
227/285
+ %ntraaortic balloon pump 1% BP2 therapy• Ksed for cardiogenic shoc7 • llo&s heart to rest
+ .entricular assist devices 1. Ds2• 'a7es over pumping for the ventricles• Ksed as a bridge to transplant
+ Destination therapy)permanent ( implantable . D + 0ardiomyoplasty ) &rap latissimus dorsi around heart + .entricular reduction )ventricular &all resected + 'ransplantH rtificial !eart +
%ntraaortic Balloon Pump 1% BP2
• Provides temporary circulatory assistance + ^ fterload
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
228/285
+ ugments aortic diastolic pressure• Outcomes
+ %mproved coronary blood flo& + %mproved perfusion of vital organs
=ntraaortic )alloon pump
% BP Machine
http://yourtotalhealth.ivillage.com/intraaortic-balloon-pump.htmlhttp://yourtotalhealth.ivillage.com/intraaortic-balloon-pump.html
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
229/285
Enhanced E,ternal0ounterpulsation)EE0P
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
230/285
Pumps during diastole)increasing O9 supply tocoronary arteries$ -i7e % BP
but not invasive$
'he 0ardiology Group( P$$
.entricular ssist Devices 1. Ds2
:entricular Assist Devices$:ADs&
•• Indications for :AD therapyIndications for :AD therapy
http://www.heartcenter.md/eecp.htmlhttp://www.heartcenter.md/eecp.htmlhttp://www.heartcenter.md/eecp.htmlhttp://www.heartcenter.md/eecp.html
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
231/285
Copyright 9 %33(< %33/< %333< 2os)y< =nc.< an affiliate of Elsevier =nc. All 1ights 1eserved.
•• E8tension of cardiopulmonary #ypassE8tension of cardiopulmonary #ypass•• Failure to (eanFailure to (ean•• Postcardiotomy cardiogenic shoc4Postcardiotomy cardiogenic shoc4
•• Kridge to recovery or cardiacKridge to recovery or cardiac
transplantationtransplantation
8Patients &ith 3e& Vor7 !eart ssociation 0lassification %. &hohave failed medical therapy
>atient Teaching'Cleveland Clinic for Heart ailure LVA7 devices
http://my.clevelandclinic.org/heart/disorders/heartfailure/lvad_devices.aspxhttp://my.clevelandclinic.org/heart/disorders/heartfailure/lvad_devices.aspxhttp://images.google.com/imgres?imgurl=http://www.texmedctr.tmc.edu/NR/rdonlyres/BF21A5C0-2D3F-4FC4-9A56-C94F18540362/389/DeBakeyYeltsin.jpg&imgrefurl=http://www.texmedctr.tmc.edu/root/en/TMCServices/News/2007/10-01/DeBakey+Gold+Medal.htm&h=201&w=300&sz=35&hl=en&start=5&um=1&usg=__kfnCWB8jKqHsftAk-j-ECVZyUko=&tbnid=MTDyDpxm9yapfM:&tbnh=78&tbnw=116&prev=/images?q=patient+teaching+ventricular+assist+devices&um=1&hl=en&safe=active&rls=GGLJ,GGLJ:2006-36,GGLJ:en&sa=Ghttp://my.clevelandclinic.org/heart/disorders/heartfailure/lvad_devices.aspxhttp://my.clevelandclinic.org/heart/disorders/heartfailure/lvad_devices.aspx
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
232/285
Schematic Diagram of -eft . D
Left ventricular assist device
http://images.google.com/imgres?imgurl=http://www.texmedctr.tmc.edu/NR/rdonlyres/BF21A5C0-2D3F-4FC4-9A56-C94F18540362/389/DeBakeyYeltsin.jpg&imgrefurl=http://www.texmedctr.tmc.edu/root/en/TMCServices/News/2007/10-01/DeBakey+Gold+Medal.htm&h=201&w=300&sz=35&hl=en&start=5&um=1&usg=__kfnCWB8jKqHsftAk-j-ECVZyUko=&tbnid=MTDyDpxm9yapfM:&tbnh=78&tbnw=116&prev=/images?q=patient+teaching+ventricular+assist+devices&um=1&hl=en&safe=active&rls=GGLJ,GGLJ:2006-36,GGLJ:en&sa=Ghttp://www.medmovie.com/mmdatabase/MediaPlayer.aspx?ClientID=65&TopicID=576http://www.medmovie.com/mmdatabase/MediaPlayer.aspx?ClientID=65&TopicID=576http://www.medmovie.com/mmdatabase/MediaPlayer.aspx?ClientID=65&TopicID=576http://www.medmovie.com/mmdatabase/MediaPlayer.aspx?ClientID=65&TopicID=576
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
233/285
Heart2ate ==
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
234/285
The Heart2ate == 'one of several ne+ LVA7 devices' designed to last longer +ith simplicityof only one moving part# also much lighter and @uieter than its predecessors# ma,or
differences is rotary action +hich creates a constant flo+ of )lood< not pumping actionB.
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
235/285
Cardiomyo!las y techniAue/ left latissimus dorsi muscle
1-DM2 transposed into chest through a &indo& created byresecting the anterior segment of 9nd rib 1; cm2$ -DM isthen &rapped around both ventricles$ Sensing and pacingelectrodes are connected to an implantable cardiomyostimulator
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
236/285
ClicD here for Tu)e
Artificial Heart animinationF
http://www.youtube.com/watch?v=oHvIwkYRFV4http://www.youtube.com/watch?v=oHvIwkYRFV4http://www.youtube.com/watch?v=oHvIwkYRFV4http://www.youtube.com/watch?v=oHvIwkYRFV4
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
237/285
Surgicaltreatment in
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
238/285
AHF,mechanical
assistdevices and
hearttransplantat
ion
$algorithm&
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
239/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
240/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
241/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
242/285
Biventricular system devices
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
243/285
9eft ventricular assist device
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
244/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
245/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
246/285
Paracorporeal ventricular assist device
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
247/285
cute Decompensated !eart "ailure1 D!"2) %npatient Management
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
248/285
Lennifer umar
"ebruary 9
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
249/285
• -earn to identify the signs and symptoms ofD!"
• -earn to interpret pertinent laboratory dataand imaging
• -earn the inpatient management of D!"
%maging/ 0hest ,)ray• Enlarged cardiac silhouette
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
250/285
• Pulmonary edema
• Pulmonary congestion + 0ephaliJation + erley B lines + Peri)bronchial cuffing
• Pleural effusions( typically bilateral
'ransition to Outpatient
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
251/285
Summary• %dentify clinical signs and symptoms of D!"
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
252/285
• Pertinent labs + Sodium( creatinine( troponin( B3P
• Relevant imaging + E G( 0CR( echocardiography
• 'reatment + Diuresis( BB( 0E%H RB( Spironolactone( Digo,in(
%sosorbide dinitrateH!ydralaJine
• 'ransition to outpatient + Strict instructions( close)follo&)up
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
253/285
briefdiscussion of
the &or7s ofthis thing$$$
"'ERloadPREload 0ontractility
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
254/285
0urrent 'reatment of cute !eart "ailure
!igh
P l d
!igh
f l d
Poor
0 ili
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
255/285
DiureticsDiuretics- S%C- S%C
ReduceReducefluidfluid
volumevolume
.asodilate.asodilate
%notropes%notropes)reduce)reduceafterload)afterload)
.asodilators.asodilators 3 3itroglycerinitroglycerin
Preload fterload 0ontractility
ugmentugment 0ontrac)0ontrac) tilitytility
Current "reatment of Acute Heart FailureCurrent "reatment of Acute Heart Failure
.asodilators
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
256/285
Diuretics
Reducefluidvolume
DecreasePreload
ndfterload
.asodilate
ugment0ontract)ility
-asi, 0E inhibitor 3itroglycerin
-asi, 3tg/ sl( top( ivMSO:
0Ei
BiP P or 0P PUU
M l i l ll f 3 i i
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
257/285
• Multiple small case reports of 3oninvasive.entilatory Support 13.S2 in patients &ithvarying diagnoses of respiratory failure$
• 3o assessment of hemodynamic findings ina controlled fashion$• 3o assessment of neurohormonal effects of
3.S$
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
258/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
259/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
260/285
Effects of 3esiritide+enous4 arterial4 coronar+A&OD#LA?#ON
HEMODYNAM#C NA?R#URE&
D#URE&
RENAL
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
261/285
rhBNP
D
R I
M
K
R
G
SS
S
SG
L
GF
CC
S S
GSGQV
M
K V LR
RH
KPS
CARD#AC#NDEK
PreloadA$terloadPC3PD spnea
CARD#AC
No increase in HRNot proarrh th"ic
Aldosterone
EndothelinNorepinephrine
&YMPA?HE?#C ANDNEUROHORMONAL &Y&?EM&
Fluid !olu"ePreloadDiureticusage
D#URE&
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
262/285
Initial and Serial Evaluation ofthe AHF Patient
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
263/285
Clinical )valuation
"e#nition of Heart FailureClassification E;ection
FractionDescription
%$ !eart "ailure &ithReduced Ejection "raction
1!" rE"2
`:
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
264/285
1! r E 2 that efficacious therapies have been demonstrated to date$%%$ !eart "ailure &ithPreserved Ejection"raction 1!" ! E"2
;
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
265/285
sy pto s o ! $0 Structural heart disease &ith prior or
current symptoms of !"$% 3o limitation of physical activity$
Ordinary physical activity does not causesymptoms of !"$
%% Slight limitation of physical activity$0omfortable at rest( but ordinary physicalactivity results in symptoms of !"$
%%% Mar7ed limitation of physical activity$0omfortable at rest( but less than ordinaryactivity causes symptoms of !"$
%. Knable to carry on any physical activity&ithout symptoms of !"( or symptoms of
!" at rest$
D Refractory !" reAuiring specialiJed
interventions$
Initial and Serial Evaluation ofthe HF Patient
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
266/285
,iagnostic Tests
"ia nostic $ests%nitial laboratory evaluation of patients presenting &ith !"
should include complete blood count( urinalysis( seruml l l d l d ( bl d
I IIaII#III
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
267/285
should include complete blood count( urinalysis( serumelectrolytes 1including calcium and magnesium2( blood ureanitrogen( serum creatinine( glucose( fasting lipid profile( liverfunction tests( and thyroid)stimulating hormone$
Serial monitoring( &hen indicated( should include serumelectrolytes and renal function$
I IIaII#III
"ia nostic $ests %cont&' 49)lead E0G should be performed initially on all patients
presenting &ith !"$
I IIaII#III
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
268/285
presenting &ith ! $
Screening for hemochromatosis or !%. is reasonable inselected patients &ho present &ith !"$
Diagnostic tests for rheumatologic diseases( amyloidosis( or pheochromocytoma are reasonable in patients presenting &ith
!" in &hom there is a clinical suspicion of these diseases$
I IIaII#III
I IIaII#III
Initial and Serial Evaluation ofthe HF Patient
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
269/285
+io!ar3ers
A!"ulatory Out%atient
A!(ulator)/*ut+atient
•%n ambulatory patients &ith dyspnea( measurement of B3P orI IIaII#III
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
270/285
%n ambulatory patients &ith dyspnea( measurement of B3P or 3)terminal pro)B)type natriuretic peptide 13')proB3P2 isuseful to support clinical decision ma7ing regarding thediagnosis of !"( especially in the setting of clinical uncertainty$
•Measurement of B3P or 3')proB3P is useful for establishing prognosis or disease severity in chronic !"$
I IIaII#III
I IIaII#III
A!(ulator)/*ut+atient%cont&'
B3P) or 3')proB3P guided !" therapy can be useful toachieve optimal dosing of GDM' in select clinically euvolemic
I IIaII#III
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
271/285
achieve optimal dosing of GDM in select clinically euvolemic patients follo&ed in a &ell)structured !" disease management program$
'he usefulness of serial measurement of B3P or 3')proB3P toreduce hospitaliJation or mortality in patients &ith !" is not&ell established$
Measurement of other clinically available tests such as
biomar7ers of myocardial injury or fibrosis may be consideredfor additive ris7 stratification in patients &ith chronic !"$
I IIaII#III
I IIaII#III
Initial and Serial Evaluation ofthe HF Patient
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
272/285
+io!ar3ers
Hos%itali=ed Acute
Hos+itali,ed/Acute
Measurement of B3P or 3')proB3P is useful to supportI IIaII#III
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
273/285
Measurement of B3P or 3 )proB3P is useful to supportclinical judgment for the diagnosis of acutely decompensated!"( especially in the setting of uncertainty for the diagnosis$
Measurement of B3P or 3')proB3P andHor cardiac troponin isuseful for establishing prognosis or disease severity in acutelydecompensated !"$
I IIaII#III
I IIaII#III
Hos+itali,ed/Acute%cont&'
'he usefulness of B3P) or 3')proB3P guided therapy forI IIaII#III
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
274/285
e use u ess o B3 ) o 3 )p oB3 gu ded t e apy oacutely decompensated !" is not &ell)established$
Measurement of other clinically available tests such as biomar7ers of myocardial injury or fibrosis may be consideredfor additive ris7 stratification in patients &ith acutelydecompensated !"$
I IIaII#III
I IIaII#III
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
275/285
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
276/285
CAK in Patients /ith S"EMI
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
277/285
Krgent 0 BG is indicated in patients &ith S'EM%and coronary anatomy not amenable to P0% &ho haveongoing or recurrent ischemia( cardiogenic shoc7(severe !"( or other high)ris7 features$
0 BG is recommended in patients &ith S'EM% attime of operative repair of mechanical defects$
I IIaII#III
I IIaII#III
CAK in Patients /ith S"EMI
I II II#III
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
278/285
'he use of mechanical circulatory support isreasonable in patients &ith S'EM% &ho arehemodynamically unstable and reAuire urgent 0 BG$
Emergency 0 BG &ithin @ hours of symptom onsetmay be considered in patients &ith S'EM% &ho donot have cardiogenic shoc7 and are not candidates forP0% or fibrinolytic therapy$
I IIaII#III
I IIaII#III
$ear failure syndromes
"or&ardN !"
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure
279/285
or&ardN ! + 8ea7ness( confusion( lo& BP + .asodilation( fluid replacement( inotropic
support
^ -. intropy( ^S.( ^ 0O( ^P OP
$ear failure syndromes left ventricular dysfunction
-eft)bac7&ardN !"
-
8/9/2019 Sinaia 2 Oct 2014 -Final-Acute Heart Failure